Literature DB >> 1346256

Loss of heterozygosity affecting the p53, Rb, and mcc/apc tumor suppressor gene loci in dysplastic and cancerous ulcerative colitis.

B D Greenwald1, N Harpaz, J Yin, Y Huang, Y Tong, V L Brown, T McDaniel, C Newkirk, J H Resau, S J Meltzer.   

Abstract

Allelic deletions of tumor suppressor genes have been observed frequently in a variety of human tumors. These losses are believed to contribute to the development of human cancer. Three of the most frequently deleted chromosomal loci contain the tumor suppressor genes p53, retinoblastoma (Rb), and mcc/apc. In order to detect loss of heterozygosity (LOH) within these genes in dysplastic and cancerous ulcerative colitis, we used an application of the polymerase chain reaction. LOH affecting p53 was observed in 8 of 17 (47%) of heterozygous patients, while LOH of Rb and the mcc/apc locus was observed in 9 of 27 (33%) and 13 of 39 (33%) of heterozygotes, respectively. Among 35 patients heterozygous at 2 or more loci, LOH of p53, Rb, and/or mcc/apc was observed in 18 (51%). LOH was more common in left-sided neoplasms. These data suggest that allelic deletion of p53, Rb, mcc, and/or apc is involved in the pathogenesis and/or progression of at least a subset of colonic dysplasias and carcinomas occurring in the setting of ulcerative colitis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1346256

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  28 in total

1.  Ki-67: a useful marker for the evaluation of dysplasia in ulcerative colitis.

Authors:  S N Andersen; T O Rognum; A Bakka; O P Clausen
Journal:  Mol Pathol       Date:  1998-12

2.  p53 mutations are associated with dysplasia and progression of dysplasia in patients with Crohn's disease.

Authors:  Jeffrey W Nathanson; Nicole E Yadron; Jeanne Farnan; Sydney Kinnear; John Hart; David T Rubin
Journal:  Dig Dis Sci       Date:  2007-08-04       Impact factor: 3.199

3.  Bcl-2 expression in colorectal tumors: evidence of different pathways in sporadic and ulcerative-colitis-associated carcinomas.

Authors:  M Ilyas; I P Tomlinson; A M Hanby; T Yao; W F Bodmer; I C Talbot
Journal:  Am J Pathol       Date:  1996-11       Impact factor: 4.307

Review 4.  Biology of colorectal cancer in ulcerative colitis.

Authors:  B A Lashner; B D Shapiro
Journal:  J Gastrointest Surg       Date:  1998 Jul-Aug       Impact factor: 3.452

Review 5.  Molecular Alterations of Colorectal Cancer with Inflammatory Bowel Disease.

Authors:  Masakazu Yashiro
Journal:  Dig Dis Sci       Date:  2015-04-04       Impact factor: 3.199

6.  Genomic instability is an early event during the progression pathway of ulcerative-colitis-related neoplasia.

Authors:  R F Willenbucher; D E Aust; C G Chang; S J Zelman; L D Ferrell; D H Moore; F M Waldman
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

7.  Loss of heterozygosity on chromosome 11p13 in primary bladder carcinoma.

Authors:  R Shipman; P Schraml; M Colombi; G Raefle; C U Ludwig
Journal:  Hum Genet       Date:  1993-06       Impact factor: 4.132

8.  K-ras mutations and p53 alterations in neoplastic and nonneoplastic lesions associated with longstanding ulcerative colitis.

Authors:  P Chaubert; J Benhattar; E Saraga; J Costa
Journal:  Am J Pathol       Date:  1994-04       Impact factor: 4.307

9.  Expression of growth factor receptor-encoded mRNA by colonic epithelial cells is altered in inflammatory bowel disease.

Authors:  R J Alexander; A Panja; E Kaplan-Liss; L Mayer; R F Raicht
Journal:  Dig Dis Sci       Date:  1995-03       Impact factor: 3.199

10.  Genomic Alterations Observed in Colitis-Associated Cancers Are Distinct From Those Found in Sporadic Colorectal Cancers and Vary by Type of Inflammatory Bowel Disease.

Authors:  Rona Yaeger; Manish A Shah; Vincent A Miller; Judith R Kelsen; Kai Wang; Zachary J Heins; Jeffrey S Ross; Yuting He; Eric Sanford; Rhonda K Yantiss; Sohail Balasubramanian; Philip J Stephens; Nikolaus Schultz; Moshe Oren; Laura Tang; David Kelsen
Journal:  Gastroenterology       Date:  2016-04-08       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.